Study to Investigate the effects single oral dose of AZD1386 (Capsaicin)
Study identifier:D5090C00009
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A double-blind, randomized, single-centre, placebo-controlled, crossover study to investigate the effects of a single oral dose of AZD1386 on intradermal capsaicin evoked pain symptoms and heat sensitivity in healthy volunteers
Medical condition
Capsaicin evoked pain
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD1386, Placebo
Sex
All
Actual Enrollment
36
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Jan 2008
Primary Completion Date: 01 May 2008
Study Completion Date: 01 May 2008
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 36 subjects receiving a specified volume of the active component AZD1386 in a single dose. | Drug: AZD1386 Oral solution fixed dose (95 mg given orally on two occasions) |
| Placebo Comparator: 2 36 subjects receiving a specified volume of placebo in a single dose. | Drug: Placebo Oral solution fixed dose (95 mg given orally on two occasions) |
Contacts
Investigators
Principal Investigator
Agneta Berg
AstraZeneca R&D Södertälje
